Notwithstanding market nervousness toward the end the first quarter of 2014 the period was characterized by a tsunami of cash flooding into biotech coffers. Both global public and private companies benefited. As a result, the sector collectively raised $9.5 billion – almost double the amount raised in the same period last year according to data from BioWorld Snapshots. Read More
While a number of analysts report that their investors show no signs of panic after the late February meltdown in all biotech stocks, they remain nervous about the sector wondering if its tremendous performance over the past two years has finally come to an end. The two-day exodus from biotech certainly contributed to ugly returns in March. Read More
A robust deal flow defined the first quarter of the year, which saw 60 global private biotech companies generate more than $1 billion. Not a bad haul and two and half times the amount generated in the same period last year from 45 deals. Read More
